Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital
→ A mixed mid-stage readout of Insmed‘s anti-inflammatory drug, INS1007, read more like a win given the low expectations for the trial back in February. Now, the FDA has stamped the drug with a vote of confidence, granting it breakthrough therapy status for the treatment of adult patients with non-cystic fibrosis bronchiectasis for reducing exacerbations. The drug, now christened brensocatib, is an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1).
→ Having made some high profile exits from companies such as Orchard and Seres, London-based VC shop 4BIO Capital last year said it intended to raise $150 million for its second fund focused on advanced therapies — including cell and gene therapy, RNA-based therapy, targeted therapy, and microbiome-based therapies — by the end of 2020. On Monday, the firm revealed that Japanese specialty pharmaceutical company Kyowa Kirin has made a strategic investment in the fund.
→ Sherlock Biosciences and Integrated DNA Technologies forged a collaboration to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for the detection of the novel coronavirus that causes Covid-19. The test kit, recently given an EUA from the FDA, is intended to increase testing capacity and decrease time to result.